Zhongmei Huadong registers Phase 3 roflumilast foam trial for seborrheic dermatitis with Arcutis
A new Phase 3 study of Roflumilast Foam 0.3% (ZORYVE) in seborrheic dermatitis was listed on ClinicalTrials.gov, sponsored by Hangzhou Zhongmei Huadong Pharmaceutical with Arcutis Biotherapeutics as collaborator.
The week's registry activity centers on one new late-stage trial for a topical foam already marketed under another name.
- A Phase 3, randomized, double blind, vehicle-controlled trial (NCT07683806) of Roflumilast foam 0.3% (ZORYVE) in trial participants with seborrheic dermatitis1 is listed as not yet recruiting. The study is sponsored by Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd., with Arcutis Biotherapeutics, Inc. as collaborator, and plans to enroll 309 participants (estimated)1, with the primary outcome being percentage of trial participants with IGA success at Week 81. Estimated start is 2026-08-24.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.